Tirzepatide
The dual-hormone successor to semaglutide - sold as Mounjaro and Zepbound. Education only; Apex doesn't supply it.
Two hormones, bigger effect.
Tirzepatide hits two gut-hormone receptors at once - GIP and GLP-1 — and in a head-to-head trial it outperformed semaglutide. It is an approved, prescription-only medicine, included here for context, not for sale.
At a glance
Where the research focuses.
Weight management
Approved for obesity; ~20% average loss, beating semaglutide head-to-head.
Type 2 diabetes
Strong blood-sugar control as Mounjaro.
Metabolic health
Broad improvements in cardiometabolic markers.
Appetite & satiety
Dual incretin signalling drives appetite reduction.
Adding a second lever.
By engaging GIP alongside GLP-1, tirzepatide pulls two metabolic levers at once - which appears to translate into greater weight loss than GLP-1 alone.
Like semaglutide, it is a fully approved drug with deep trial evidence, not a research compound.
Strength of the evidence.
- SURMOUNT phase-3 RCTs
- Head-to-head superiority vs semaglutide
- FDA approval (obesity & diabetes)
- Sleep-apnoea and metabolic benefits
- Real-world effectiveness
- Compounded 'research' versions (quality risk)
- Long-term use questions
How it works
Dual agonism
Activates GIP and GLP-1 receptors together.
EstablishedAppetite
Reduces appetite and food intake.
ClinicalGlucose control
Improves insulin response, lowers glucose.
EstablishedSide effects
GI effects common, like other incretins.
DocumentedTirzepatide is a prescription medication (Mounjaro / Zepbound), patent-protected. Apex does not sell it. Gray-market versions carry quality, safety and legal risks; legitimate access is by prescription. Information only.
- For research purposes only
- Not for human consumption
- Not FDA approved
- Consult a qualified professional